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A B S T R A C T
As cellular immunity is essential for virus clearance, it is commonly accepted that no
adequate cellular immunity is achieved by all available inactivated HA-based inﬂuenza
vaccines.
Thus, an improved inﬂuenza vaccine to induce both humoral and cell-mediated
immune responses is urgently required to control LPAI H9N2 outbreaks in poultry farms.
M2e-based vaccines have been suggested and developed as a new generation of
universal vaccine candidate against inﬂuenza A infection.
Our previous study have shown that a prime-boost administration of recombinant
4  M2e.HSP70c (r4M2e/H70c) fusion protein compared to conventional HA-based
inﬂuenza vaccines provided full protection against lethal dose of inﬂuenza A viruses in
mice. In the present study, the immunogenicity and protective efﬁcacy of (r4M2e/H70c)
was examined in chickens.
The data reported herein show that protection against H9N2 viral challenge was
signiﬁcantly increased in chickens by injection of r4M2e/H70c compared with injection of
conventional HA-based inﬂuenza vaccine adjuvanted with MF59 or recombinant 4  M2e
(r4M2e) without HSP70c. Oropharyngeal and cloacal shedding of the virus was detected in
all of the r4M2e/H70c vaccinated birds at 2 days after challenge, but the titer was low and
decreased rapidly to reach undetectable levels at 7 days after challenge. Moreover,
comparison of protective efﬁcacy against LPAI H9N2 in birds intramuscularly immunized
with r4M2e/H70c likely represented the ability of the M2e-based vaccine in providing
cross-protection against heterosubtypic H9N2 challenge and also allowed the host
immune system to induce HA-homosubtype neutralizing antibody against H9N2
challenge.
 Corresponding author. Tel.: +98 261 4570038 46; fax: +98 261 4552194.
E-mail addresses: sme3422@gmail.com, smebrahimi@shirazu.ac.ir (S.M. Ebrahimi).
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Avian inﬂuenza viruses (AIVs) pose a threat toward the
ealth of both poultry and human population worldwide.
owever, in many countries, low pathogenic avian
ﬂuenza H9N2 (LPAI H9N2) viruses are an enormous
conomic burden on the commercial poultry industry
hen they cause signs of mild respiratory disease and a
eduction in egg production (Alexander, 2003; Senne,
003). Some reports also revealed that the LPAI H9N2
iruses in domestic poultry farms resulted in sever clinical
igns and high mortality depending on the viral strain as
ell as co-infection with other pathogens or immunosup-
ressive diseases (Bano et al., 2003; Kishida et al., 2004).
Vaccination using conventional HA-based vaccine is the
ajor tool for the prevention and control of LPAI H9N2
iruses in the poultry industry where the HA of the vaccine
train matches that circulating virus (Boni, 2008; Sun et al.,
012).
Conventional HA-based inﬂuenza vaccine has been
roved to elicit strong humoral responses and can prevent
linical disease and reduce viral shedding in ﬁeld condi-
ons, but it cannot prevent vaccinated poultry from
ecoming infected and from shedding wild viruses in
rm settings (Swayne and Halvorson, 2003; Sun et al.,
012).
Moreover, in contrast to hemagglutinin (HA) protein,
e matrix protein 2 (M2e) of inﬂuenza virus is not
ccessible to antibody and therefore antibodies to M2e are
ot virus-neutralizing. However, it was reported that anti-
2e antibodies can bind to the M2e protein on infected
ost cells and reduce virus replication by interfering with
irus budding and by mediating the killing of infected cells
y complement or by cells of the innate immune system
egerlehner et al., 2004; Subbarao and Joseph, 2007;
ozdzanowska et al., 1999).
As cellular immunity is essential for virus clearance, it is
ommonly accepted that no adequate cellular immunity is
chieved by currently available inﬂuenza vaccine (Choi
t al., 2008; Wareing and Tannock, 2001).
Thus, an improved inﬂuenza vaccine to induce both
umoral and cell-mediated immune responses is urgently
equired to control LPAI H9N2 outbreaks in poultry farms.
Additionally, conventional HA-based vaccines are
ainly designed to induce subtype-speciﬁc neutralizing
ntibodies and do not protect against infection with other
ﬂuenza subtypes or with antigenic variants (Fan et al.,
007; Brett and Johansson, 2005). Hence, new vaccination
trategies that will result in broad cross-reactivity against
ﬂuenza viruses need to be developed.
So far, several approaches have been investigated to
develop broadly protective vaccines and focus mainly on
the conserved region of the viral matrix protein-2 (M2)
protein of inﬂuenza A virus. M2e-based vaccines have been
suggested and developed as a new generation of universal
vaccine candidate against inﬂuenza A infection.
Indeed, M2e protein with different constructions,
including ones from our laboratory, revealed a high
potential as a vaccine for prevention of highly pathogenic
(homologous and heterologous) inﬂuenza A viruses in
animal models (Misplon et al., 2010; Fan et al., 2004;
Slepushkin et al., 1995; Frace et al., 1999; Neirynck et al.,
1999; Mozdzanowska et al., 2003; Huleatt et al., 2008;
Song et al., 2011; Ebrahimi et al., 2012; Zabeh Jazi et al.,
2012). Previous studies have reported on antibodies and
cell-mediated cytotoxicity speciﬁc to the M2e antigen and
their anti-viral activity (Jegerlehner et al., 2004). It was
shown previously that nucleotide based CpG oligodeox-
ynucleotides (CpG-ODN) adjuvant with M2e peptide and
Escherichia coli expressed M2e protein fused with activa-
tion associated protein-1 (ASP-1) or Salmonella typhimur-
ium ﬂagellin proteins 2 (STF2) adjuvant signiﬁcantly
induced both humoral and cell-mediated immune
responses in mice with M2e-speciﬁc IgG2a and IFN-g
secreting lymphocytes (Wu et al., 2009; Zhao et al., 2010;
Huleatt et al., 2008).
In our previous study, it was shown that a prime-boost
administration of 4  M2e.HSP70c without adjuvant by
intramuscular route in mice (Balb/c) provided full protec-
tion against lethal dose of mouse-adapted H1N1, H3N2, or
H9N2 inﬂuenza A isolates circulating in Iran. However,
protection induced by immunization with 4  M2e.HSP70c
failed to prevent weight loss in challenged mice, but they
experienced signiﬁcantly lower weight loss, clinical
symptoms and higher lung viral clearance in comparison
with protective effects of conventional inﬂuenza vaccines
in challenged mice (Ebrahimi et al., 2012).
To date, the available data to describe immune
responses in chicken after the administration of M2e-
based vaccine candidates are very limited. However, it was
shown that salmonella-vectored vaccine expressing M2e
in association with CD154 (CD40 ligand) protected
chickens against low pathogenic AI (Layton et al., 2009).
Hence, in agreement with the above mentioned
ﬁndings, this article describes for the ﬁrst time the use
of r4M2e/H70c fusion protein expressed in E. coli to
vaccinate chickens, a target host of avian inﬂuenza in a
manner of case-control study. Furthermore, the humeral
and cell-mediated responses elicited against r4M2e/H70c
was analyzed with regard to antibodies and cytokines
This protective immunity might be attributed to enhanced cell-mediated immunity,
which is interpreted as increased lymphocytes proliferation, increased levels of Th1-type
(IFN-g) and Th2-type (IL-4) cytokines production and increased CD4+ to CD8+ ratios,
resulting from the injection of four tandem repeats of the ectodomain of the conserved
inﬂuenza matrix protein M2 (4  M2e) genetically fused to C-terminus of Mycobacterium
tuberculosis HSP70 (mHSP70c).
 2014 Elsevier B.V. All rights reserved.
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M. Dabaghian et al. / Veterinary Microbiology 174 (2014) 116–126118oduction. Virus challenge experiments were also
sayed to evaluate the protective efﬁcacy of r4M2e/
0c against heterosubtypic avian inﬂuenza virus, H9N2,
 chicken lungs.
 Material and methods
. Virus
As previously described (Ebrahimi et al., 2011), the
allenge strain was inﬂuenza A/Chicken/Iran/339/2002
N2 low pathogenic isolated from a commercial layer
rm at 53 wk of age, showing severe inﬂuenza clinical
ns including respiratory distress, swelling of the
fraorbital sinuses, and conjunctivitis accompanied with
0% morbidity and high mortality. There was also a 60% to
% decrease in egg production, along with misshapen,
hitish, and fragile eggs.
Avian inﬂuenza H9N2 virus strain as the challenge
oculum was passed one additional time in the allantoic
cs of speciﬁc pathogen-free (SPF) fertile chicken eggs and
en calculated as a median embryo infectious dose
ID50) per milliliter by the Reed and Muench method
eed and Muench, 1938). Clariﬁed allantoic ﬂuids were
quoted and then stored at 70 8C.
. Chickens
All experimental procedures were carried out in
cordance with the guidelines and with the approval of
e local institutional animal experiment committee
nimal rearing Dept., Baqiyatallah University of Medical
iences, Tehran, Iran). One-day-old broiler chickens
ommercial name Ross) were acquired from a local
pplier (Amol Joojeh Co., Iran). After 2 weeks in the
ooders with free access to water and a standard starter
et, the chickens were divided into ﬁve 25-bird groups,
ed for baseline serology, transferred to separate location
here they were vaccinated and kept until the end of the
perimental period.
Before the experiments, all animals were conﬁrmed to
 free of avian inﬂuenza subtype H9 antibody by the
magglutination inhibition (HI) test. After challenge,
rds were examined daily for clinical signs of disease.
. Vaccines and immunization
Recombinant 4  M2e (r4Me2) and 4  M2e.HSP70c
sion protein (r4M2e/H70c) with the M2e consensus
sequence of human inﬂuenza A virus (H1N1, H2N1, H3N2;
amino acid sequence: SLLTEVETPIRNEWGCRCNDSSD) was
expressed, puriﬁed and prepared as a vaccine candidate
from an E. coli expression system as previously described
(Ebrahimi et al., 2012).
The puriﬁed recombinant proteins were stored in F105
buffer which contains 10 mM Tris, 10 mM histidine, 5% (w/
v) sucrose, 75 mM NaCl, 0.1 mM EDTA, 0.5% (v/v) ethanol
and 0.02%(w/v) polysorbate-80 (pH 7.2) at 4 8C until use.
The mixture contained 30 mg of r4M2e/H70c or r4M2e
per dose (0.5 ml/bird) and was used as recombinant M2e-
based inﬂuenza vaccines.
Avian inﬂuenza H9N2 virus strain A/Chicken/Iran/101/
1998 (Iran/H9N2) was kindly provided by the Marand
branch of Iran’s Razi Vaccine and Serum research Institute.
Virus was inoculated into the allantoic cavities of 10-day-
old embryonated eggs and was harvested after 72 h
incubation at 35 8C. The AIV titer of the inoculated allantoic
ﬂuid was 109.3 50% egg infectious dose per milliliter (EID50/
ml). Then, the virus was inactivated by adding 0.2% formalin
(v/v) and kept at 37 8C for 24 h. Inactivation was conﬁrmed
by the absence of detectable infectivity after two blind
passages of formalin treated allantoic ﬂuid in embryonated
eggs. The inactivated allantoic ﬂuid was adjuvanted with
MF59 (Novartis’ proprietary squalene based oil-in-water
nano-emulsion) in a volume ratio 50:50 and was used as a
conventional HA-based inﬂuenza vaccine (Con/HA) for the
following experiments. Allantoic ﬂuid containing infectious
virus was also used as an antigen source for HI assay.
Chickens were randomly divided into 5 treatment
groups of 25 birds each (Table 1) and tagged for individual
identiﬁcation.
All birds in the appropriate groups as shown in Table 1
were each immunized twice (days 10 and 20) intramus-
cularly (IM) in the pectoral muscle with a dose of 0.5 ml.
Birds of group NC as an uninfected control was kept in the
separate room.
2.4. Virus challenge experiment and sampling
Ten days after the ﬁnal immunization (day 30),
chickens were challenged by intra-nasal inoculation of
A/Chicken/Iran/339/2002 H9N2 low pathogenic at a dose
of 106.8 EID50 in 100 ml of PBS per bird. Challenged chickens
were monitored daily for 14 days after infection for the
apparition of clinical signs (reluctance to move, anorexia,
congestion of eyes, respiratory signs mainly sneezing, and
swollen head). Body weight gains were also measured
between days 30 and 44.
ble 1
ﬁnitions of experimental groups.
roup No. of immunized
birds
Deﬁnition
C 25 Negative control group given F105 buffer intramuscularly at 10 and 20 days of age
C 25 Challenge control group given F105 buffer intramuscularly at 10 and 20 days of age
on/HA 25 Group given conventional HA-based inﬂuenza vaccine intramuscularly at 10 and 20 days of age
4M2e/H70c 25 Group given 30 mg/bird of recombinant 4  M2e.HSP70c fusion protein formulated with F105 buffer
intramuscularly at 10 and 20 days of age
4M2e 25 Group given 30 mg/bird of recombinant 4  M2e fusion protein (without HSP70c) formulated with F105
buffer intramuscularly at 10 and 20 days of age
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M. Dabaghian et al. / Veterinary Microbiology 174 (2014) 116–126 119Blood samples were taken from challenged birds on
ays 7 and 14 after infection for HA-antibody titration
sing hemagglutination inhibition (HI) technique.
Protection was expressed as the percentage of live and
ealthy birds at 14 days post-challenge.
Oropharyngeal and cloacal swabs were collected on
ays 2, 4, and 7 post-challenges from 5 challenged birds in
ach group to evaluate virus shed titers. These time points
epresent the peak in oropharyngeal and cloacal shedding,
espectively (Spackman et al., 2010; Le Gall-Recule´ et al.,
007).
Swab tips were transferred to 1 ml viral transport
edium containing antibiotics and antimycotics com-
ounds (Gibco, Grand Island, NY, USA), vortexed brieﬂy
nd medium was either frozen at 80 8C.
.5. Virus titration from swabs
Virus titers were determined as the 50% tissue culture
fectious dose (TCID50) as described previously (Chen
t al., 2007; Qiu et al., 2006). MDCK cells (a kindly gift from
r. Mirjalili, Razi Vaccine and Serum Research Institute)
ere inoculated with a 10-fold serial dilution of sample
nd incubated at 37 8C in a humid atmosphere of 5% CO2 for
 h. After 1 h of absorption, media was removed and
verlay medium containing L-1-tosylamido-2-phenylethyl
hloromethyl ketone (TPCK) trypsin (Thermo Fisher
cientiﬁc, Rockford, USA) was added to the infected cells
nd incubated for 3 days. Viral cytopathic effects were
bserved daily, and titers were determined by the HA test.
or HA, chicken red blood cells (0.5%) were added to 50 ml
f cell supernatant and incubated for 30 min. The virus
ter of each sample was expressed as 50% tissue infected
oses using the Reed-Muench method.
.6. Serological analysis
Pre-vaccination sera were collected from all vaccinated
hickens. Five chickens were sampled randomly from each
roup on days 20 and 30 after immunization and blood
amples were collected via wing vein puncture. Sera at a
:400 dilution prepared in PBS were tested for develop-
ent of M2e- or HA-speciﬁc antibodies.
Serum samples, ﬁve birds from each group, were also
ollected from the surviving birds on days 7 and 14 post-
hallenge for detection of HA speciﬁc antibody responses.
erum samples from all groups and all time points were
eat inactivated at 56 8C for 30 min before being analyzed
 ELISA or hemagglutinin inhibition (HI) assays for
nalysis of anti-M2e or HA-antibody responses, respec-
vely. All negative samples for the HI test were set at
 log2, all negative samples for the ELISA test were set at
.5 OD, and all negative samples for the virus titration test
ere set at 0.9 log10 EID50/ml.
The HI assay was carried out according to our previous
tudy (Ebrahimi et al., 2011) using formalin-treated Iran/
9N2 antigen and 1% v/v suspension of chicken red blood
ells (RBCs). All samples were analyzed on the same day,
nd HI titers were scored as the reciprocal of the highest
erum dilution producing 50% inhibition of hemagglutina-
on.
The ELISA assay was performed as described previously
(Ebrahimi et al., 2012). Brieﬂy, 96 well plates (Maxisorb,
Nunc, Denmark) were coated either with 1 mg/ml of
synthetic M2e-peptide (23 amino acids, 2 to 24, SLLTE-
VETPIRNEWGCRCNDSSD, synthesized by solid phase
technology at the GL Biochem, China), in 50 mM sodium
bicarbonate buffer, pH 9.6, and incubated overnight at 4 8C.
After blocking, different serum samples were loaded on
peptide coated plates. The plates were incubated with the
different serum samples and then incubated with 1:10000
goat anti-chicken IgG-HRP conjugates (Sigma-Aldrich,
USA), for 1 h at 37 8C. The color reaction was developed
with 3,30,5,50-tetramethylbenzidine, TMB, (Pishtazteb,
Tehran, Iran), at OD 450 nm. For comparison between
groups, the averages of A450 values of different sera were
analyzed. The antibody titer is deﬁned as the reciprocal of
the highest dilution that yields an OD 450 nm value above
2 times the mean of negative control wells.
2.7. Lymphocyte proliferation and immunophenotyping
assays
An antigen speciﬁc lymphocyte proliferation assay was
performed using a modiﬁed MTT method as described
previously (Kong et al., 2004; Mosmann, 1983). Ten days
after the ﬁnal immunization (day 30), blood samples from
5 birds each group which were chosen for serological assay
on day 30 after immunization were collected for lympho-
cyte separation via wing vein puncture in 2.5 ml syringes
preloaded with 0.2 ml sodium heparin.
The cell suspension from the blood was layered on
Ficoll-Paque lymphocyte separation medium by density
gradient centrifugation. Peripheral blood lymphocytes
(PBLs) were obtained from the interface and washed twice
with Hanks’ balanced salt solution. After centrifugation,
the ﬁnal pellet was resuspended in RPMI 1640 medium
(Gibco, Grand Island, NY, USA) containing 5% heat-
inactivated fetal calf serum at a concentration of 2  106
cells per ml and seeded in a 96-well plate in triplicate
(3  105 cells per well).
Cultures were stimulated under various conditions
included treatment with 5 m/ml concanavalin A (Sigma-
Aldrich, USA) as a positive control, 5 mg/ml synthetic M2e-
peptide as a speciﬁc antigen, 5 m/ml bovine serum albumin,
BSA, (Sigma-Aldrich, USA) as an irrelevant antigen or RPMI
1640 medium without antigen as a negative control.
After 60 h of incubation at 37 8C in a humid atmosphere
with 5% CO2, 20 ml of MTT (Sigma-Aldrich, St. Louis, MO)
was added to each well and the incubation was continued
for another 4 h. Then 100 ml of dimethyl sulfoxide (DMSO)
was added, and incubation was continued for an additional
24 h before measurement of OD at 570 nm (OD570) using
an ELISA reader (Bio-Tek Instruments, VT). The stimulation
index (S.I.) was calculated as the ratio of the average OD of
antigen-stimulated cells to the average OD of unstimulated
cells.
For examination of changes in T cell populations, 100 ml
of PBLs isolated as described above was incubated for 1 h at
4˚ C with the following antibodies (double labelling):
monoclonal antibody phycoerythrin (PE)-labeled anti-
chicken CD3+ and then with PE-labeled anti-chicken
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M. Dabaghian et al. / Veterinary Microbiology 174 (2014) 116–1261204+ or ﬂuorescein isothiocyanate (FITC)-conjugated anti-
icken CD8+ (Southern Biotechnology, USA).
PE- and FITC-conjugated isotype controls were also
cluded. Cells were analyzed by ﬂuorescence-activated
ll sorting (BD Biosciences).
. Cytokine assays
Aliquots of the same PBLs samples used to set up the
mphocyte proliferation assay were tested for the
oduction of IFN-g and IL-4 cytokines with commercial
icken IFN-g and IL-4 sandwich ELISA kits (Biosource,
ina).
Sterile 96 well round bottom plates at 4  105 cells per
ell in triplicate containing 5 mg/ml synthetic M2e-
ptide was used in the assay. Control wells were
epared by adding 500 ml complete RPMI alone (nega-
e control).
For the IFN-g and IL-4 detection, plates were centri-
ged for 10 min at 600  g after 48 h incubation at 37 8C in
CO2 incubator. Supernatants from the spun plates were
llected and then analyzed for detection of chicken Th1-
pe cytokine (IFN-g) and Th2-type cytokine (IL-4)
cretion as described in kit instruction manual.
Brieﬂy, standards or samples were added to the
propriate pre-coated plate wells with Horseradish
roxidase (HRP) conjugated antibody preparation spe-
c for IFN-gamma or IL-4. The competitive inhibition
action was launched between pre-coated antigens and
propriate cytokines in samples. A substrate solution
as added to the wells and the color develops in opposite
 the amount of cytokines in the samples. The color
velopment was stopped and the intensity of the color
as measured. The concentrations of cytokines secretion
 the samples were determined from the standard
rves.
. Statistical analysis
Data were analyzed using the SPSS 13.0 software (SPSS
c., Chicago, USA). Data were analyzed for signiﬁcance
 < 0.05) by the one-way analyses of variance when
riance between groups was homogeneous and distribu-
n of the data was normal or a nonparametric test
ruskal–Wallis) when normality test or homogeneity of
riance test failed.
3. Result
3.1. Serologic response to immunization
The analysis of pre-vaccination swabs and serum
samples by virus isolation and HI tests revealed that
all birds used in this study had no detectable infection
with H9 viruses and the levels of HI antibody titers
were <2 log2 against these virus subtypes (data not
shown). The uninfected control groups remained
healthy throughout the experiment and showed no
clinical disease signs. H9N2-speciﬁc HI titers remained
at baseline values (2 log2) in the serum samples
recovered from this control group just before termination
of the experiments.
Serum from chickens immunized with M2e-based
vaccines or HA-based vaccine were analyzed by ELISA
and HI assays to identify antibodies directed against M2e
peptide or HA glycoprotein of inﬂuenza A isolates,
respectively.
All birds initially immunized and subsequently boosted
with M2e-based vaccine or conventional vaccines contain-
ing HA had an anti-M2e (Fig. 1) and anti-HA (Fig. 2)
antibody responses as measured by ELISA and HI assays,
respectively.
No anti-M2e antibody was detected in birds immunized
with Con/HA (Fig. 1). There was statistically signiﬁcant
difference in induced anti-M2e antibodies among M2e-
based immunized groups of birds only after boosting, in
that birds immunized with r4M2e/H70c recombinant
fusion protein showed higher titer of anti-M2e antibody
than observed with r4M2e (Fig. 1; P < 0.05). The results
suggested that mHSP70c could induce enhanced humoral
responses against the M2e protein.
No anti-HA antibody was produced in birds immu-
nized with r4M2e/H70c as measured by HI assay, prior to
viral challenge. However, the mean titers of antibodies
enhancement with HA glycoprotein were detected in
birds vaccinated with r4M2e/H70c or r4M2e or Con/HA
on days 7 and 14 after challenges by using homologous
formalin-treated viruses antigen (Fig. 2). These data
conﬁrm that inactivated conventional HA-based vaccine
or M2e-based vaccines could not fully prevent infection
in birds. However, r4M2e/H70c fusion protein as a
vaccine candidate signiﬁcantly decreased viral shedding
and clinical signs in challenged birds (Tables 2 and 3).
ble 2
tective efﬁcacy of prime—boost strategies in chickens against H9N2 virus challenge.
roup Virus isolation from swabs on different days p.c.: no. of shedding birds/total (mean titers [log10 TCID50/ml] S.E.M)
Day 2 Day 4 Day 7
Oropharyngeal Cloacal Oropharyngeal Cloacal Oropharyngeal Cloacal
C 0/25 (0) 0/25 (0) 0/25 (0) 0/25 (0) 0/25 (0) 0/25 (0)
C 25/25 (4.9  0.5)* 12/25 (3.4  0.5) 25/25 (6.2  0.6) 22/25 (5.5  0.4) 10/25 (4.2  0.4) 5/25 (2.7  0.1)
on/HA 25/25 (3.6  0.3) 8/25 (2.4  0.4) 25/25 (4.7  0.4) 17/25 (4.3  0.3) 11/25 (3.3  0.3) 0/25 (0)
4M2e/H70c 25/25 (4.1  0.2) 11/25 (2.5  0.2) 25/25 (3.6  0.2) 15/25 (3.5  0.2) 0/25 (0) 0/25 (0)
4M2e 25/25 (4.4  0.4) 11/25 (2.7  0.2) 25/25 (5.4  0.4) 19/25 (4.5  0.3) 14/25 (3.5  0.3) 0/25 (0)
te: Deﬁnition of each group is given in Table 1.
 Numbers show log10 geometric mean TCID50/ml standard error of the mean (S.E.M) of ﬁve birds/group per time point.
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To determine and compare the protective efﬁcacy among
ifferent vaccinated groups, all of the immunized chickens
ere challenged intranasally with 106.8 EID50/0.1 ml of
H9N2 AIV. Clinical signs, protection rates and viral
shedding after challenge of chickens are summarized in
Tables 2 and 3.
In all experimental groups, protective efﬁcacy among
immunized chickens following challenge was monitored
ig. 2. Mean hemagglutinin-inhibition (HI) antibody titers from birds immunized with Con/HA, r4M2e, and r4M2e/H70c 10 days after the ﬁrst immunization
st immun) and the second immunization (boost 1), respectively. Formalin-treated Iran/H9N2 antigen was used in HI assay for analysis of anti HA-antibody
sponses induced by conventional vaccines. The mean titers of antibodies enhancement with HA glycoprotein were detected in birds vaccinated with r4M2e or
M2e/H70c on 7 and 14 day post infections (7DPI and 14DPI) by using homologous formalin-treated Iran/H9N2 antigen. Bars show log 2 geometric
ig. 1. M2e speciﬁc antibodies (1:400 diluted in PBS) were determined by ELISA. 96-well plates were coated with peptide M2e. Anti-sera were collected
3 days after the ﬁrst immunization (1st immun) and the second immunization (boost 1), respectively, from mice immunized with 4  M2e.HSP70c
dministrated in F105 buffer. The bound antibodies were detected by horseradish peroxidase-linked rabbit-anti-mouse antibodies and TMB solution. Mean
alue  S.E.M of A450 in each group were presented. The titers of antibodies were expressed as the highest dilution of a serum which has twice average value of
450 in control group. Bars show mean value  standard error of the mean (S.E.M) of ﬁve birds/group per time point. The dashed line shows the limit of detection.
tatistically signiﬁcant differences (P < 0.05) are indicated by * (compared with NC or Con/HA) or ** (compared with r4M2e alone).ean  standard error of the mean (S.E.M) of ﬁve birds/group per time point. The dashed line shows the limit of detection. Statistically signiﬁcant differences
 < 0.05) are indicated by * (compared with other groups on 7 and 14 day post infections). (Infection) indicates as before () or after (+) infection.
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mptoms.
From day 3 after viral challenges, the challenged and
n vaccinated birds (CC group) developed obvious clinical
ns including: general depression, sneezing, respiratory
unds, rufﬂed feathers, and eye redness. Clinical signs
ere observed from 2 to 8 days post-challenge and birds
ere quiet and reluctant to move.
These clinical signs were delayed for 2 days in the birds
ccinated with the r4M2e/H70c, r4M2e or Con/HA, in
hich they exhibited mild clinical signs for 2–3 days.
By day 5 post-challenge, the birds immunized with
M2e/H70c showed some recovery. On day 7 post-
allenge, they were behaving normally and their activity
d appetite returned to normal levels.
As shown in Table 3, the birds immunized with r4M2e/
0c showed weight loss following the viral challenge;
wever, this was less severe than that observed for the
allenged non-vaccinated birds (group CC) and birds
ccinated by Con/HA or r4M2e vaccines. The difference in
ean body weight loss of r4M2e/H70c immunized group
 birds following viral challenges with compared to other
oups of challenged birds was also highly signiﬁcant
(Table 3; P < 0.05). There was no signiﬁcant difference in
mean body weight loss between r4M2e/H70c immunized
group of birds and unchallenged birds (NC group). It is
concluded that weight loss is associated with the viral load
of H9N2 virus in birds.
None of the chickens immunized with r4M2e/H70c or
Con/HA vaccines died after challenge, whereas six of the
25 chickens injected with the F105 buffer (CC group) and
three of the 25 chickens immunized with r4M2e died from
the disease.
To measure virus shedding, oropharyngeal and cloacal
swabs were obtained from all chickens on days 2, 4 and
7 post-challenge and assessed by virus titration in MDCK
cells. As shown in Table 2, no virus was isolated from the
oropharyngeal and cloacal swabs of the unchallenged birds
(NC group). All challenged birds showed respiratory viral
replication at days 2, and 4 after challenges with LPAI
H9N2 virus. The birds immunized with r4M2e/H70c had
overall signiﬁcantly lower oropharyngeal and cloacal viral
shedding than did the challenged CC, r4M2e or Con/HA
vaccinated birds (Table 2; p < 0.05).
At day 7 post-challenge, no viruses were detected in the
birds immunized with r4M2e/H70c; whereas, viruses were
ble 3
nical signs and mortality in immunized chickens after challenge with LPAI H9N2 virus.
roup No. of challenged birds Clinical signs Mortality
No. of sick birds/total (%) BW (g  S.D.)* No. of dead birds/total (%)
C 25 0/25 (0) 710  2 2 a 0/25 (0)
C 25 25/25 (100) 460  77 b 6/25 (24)
on/HA 25 23/25 (92) 545  43 c 0/25 (0)
4M2e/H70c 25 25/25 (100) 670  14 a 0/25 (0)
4M2e 25 25/25 (100) 510  35 c 3/25 (12)
ta within BW column with different letters are signiﬁcantly different (P < 0.05).
 Body weight was measured 14 days post-challenge (p.c.).
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eriods of viral shedding, the birds that received r4M2e/
70c had lower periods of virus replication.
.3. Levels of Th1 and Th2 cytokines
We investigated the effect of r4M2e with and without
SP70c on changes in Th1 and Th2 phenotypes. As shown in
ig. 3, the increase in the production of IFN-g (Th1-type) and
-4 (Th2-type) after r4M2e/H70c was signiﬁcantly higher
an that after injection of r4M2e alone when stimulated
ith synthetic M2e peptide, whereas the chickens vacci-
ated with con/HA or F105 buffer did not respond to the M2e
eptide (P < 0.05). This proﬁle of cytokine secretion
uggested that mHSP70c enhances the induction of immune
esponses by promoting a Th1-dominant response.
.4. Lymphocyte proliferation assay
The cellular immune response was examined by
etermining the ability of chicken peripheral mononuclear
ells to show a proliferative response against synthetic
2e peptide. As shown in Fig. 4, an enhanced T-cell
roliferative response to M2e peptide was clearly observed
in the groups immunized with r4M2e/H70c or r4M2e
when stimulated with synthetic M2e peptide, whereas the
chickens vaccinated with con/HA or F105 buffer did not
respond to the M2e peptide.
The level of the T-cell proliferative response in the
group immunized with r4M2e/H70c was signiﬁcantly
higher than that in the group immunized with r4M2e
(P < 0.05). Chickens in all groups responded similarly to
stimulation with ConA (P > 0.05).
These results indicated that higher levels of M2e-
speciﬁc T-cell proliferative responses could be elicited by
immunization with r4M2e/H70c fusion protein than by
immunization with r4M2e alone.
3.5. Immunophenotyping of peripheral T cells
As CD4+ and CD8+ T-lymphocytes are among the most
crucial components of antiviral effectors, these lymphocytes
were assessed in immunized chickens. Flow cytometric
analysis of unstimulated cells was used to standardize the
background responses. As shown in Table 4, immunization
with M2e-based vaccine (r4M2e/H70c or r4M2e) or HA-
based vaccine (Con/HA) signiﬁcantly increased the percen-
tages of CD4+CD3+ and CD8+CD3+ T-lymphocytes compared
0
1
2
3
4
5
6
CNe2M4rc07H/e2M4rAH/noC
St
am
ul
at
io
n 
in
de
x
ConA
M2e
BSA
*
**
ig. 4. Peripheral blood T-lymphocyte proliferation assay. The test was repeated three times and values are expressed as mean  S.E.M. Statistically
gniﬁcant differences (P < 0.05) are indicated by * (compared with NC or Con/HA) or ** (compared with r4M2e alone). ConA, Concanavalin A.
able 4
atios of CD4+ to CD8+ T lymphocytes after ﬁnal vaccination.
Group Week post vaccination
1 2 3 4
Con/HA 1.84  0.25 a 1.81  0.21 a 1.79  0.15 a 1.80  0.09 a
r4M2e/H70c 2.08  015 b 2.17  0.11 b 2.05  0.23 b 2.02  0.21 b
r4M2e 1.66  0.14 c 1.65  0.08 c 1.63  0.12 c 1.59  0.15 c
NC 1.46  0.13 d 1.45  0.09 d 1.42  0.22 d 1.38  0.15 d
ata are expressed as means  S.E.M. Data are presented as percentage of total cells.
ata within a column with different letters are signiﬁcantly different (P < 0.05).
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ffer (P < 0.05).
There was a signiﬁcant difference in the percentages of
4+CD3+ and CD8+CD3+T-lymphocytes between the group
munized with r4M2e/H70c and the group immunized
ith r4M2e or Con/HA (P < 0.05). The ratios of CD4+ to CD8+
mphocytes in r4M2e/H70c vaccinated group was signiﬁ-
ntly higher than in groups immunized with r4M2e or Con/
 from the ﬁrst week after vaccination (Table 4, P < 0.05).
ese results showed that the r4M2e/H70c can elicit a
llular immune response in chickens signiﬁcantly.
 Discussion
Avian inﬂuenza virus (AIV) is one of the most important
spiratory pathogens which annually pose signiﬁcant
blic health concern and devastating economic losses to
e commercial poultry, especially chickens industry,
orldwide (Alexander, 2003; Senne, 2003).
Up to now, vaccination has played an important role in
e protection of chickens against AIV infections. Currently
ailable inﬂuenza vaccine used in chickens is inactivated
hole virion that only induce strong neutralizing antibody
eciﬁc for the highly variable surface hemagglutinin (HA)
ycoprotein, and it is commonly accepted that no
equate cellular immunity is achieved (Moscona, 2005;
areing and Tannock, 2001).
Neutralizing antibodies exert strong immune pressure
 inﬂuenza virus to mutate and reassort continuously and
us could escape from vaccine protection, leaving hosts
ly partially protected against the next inﬂuenza infec-
n (Sun et al., 2012). Thus, cellular immunity is essential
r virus clearance and an improved AIV vaccine is needed
 induce complete immunity against drift variants within
subtype of AIVs in poultry industry.
This study was conducted to evaluate the immunoge-
city and protective efﬁcacy of an E. coli-expressed
 M2e.HSP70c fusion protein comprising C-terminus of
ycobacterium tuberculosis HSP70 (mHSP70c) genetically
sed to four tandem repeats of the ectodomain of the
nserved inﬂuenza matrix protein M2 (M2e) using
icken as the target host for AIVs.
The aim of universal inﬂuenza vaccination approaches
to provide long-lasting protection against a wide range
 viral serotypes. Hence, M2e protein-based vaccine
proaches represent one such vaccine as its N-terminal
itope SLLTEVET (residues 2–9) found to be conserved at
rate of over 99.3% among all subtypes of inﬂuenza A
ruses (Fiers et al., 2004; Liu et al., 2005).
The reason of linking M2e to adjuvant portion of
HSP70 is that the targeting of antigen to APCs through
P70 receptors such as CD91 is a useful strategy to induce
8 T cell and antibody responses by alternate MHC-I Ag
ocessing (cross-processing) mechanisms, resulting in
oss-presentation of the exogenous antigens to CD8T cells
at are crucial to immune responses against viruses
rnold et al., 1995; Blachere et al., 1997; Tobian et al.,
04). Moreover, Hsp70 can also activate the innate
munity through CD40 and Toll-like receptor-2 (TLR-2)
d TLR-4 to induce cytokine secretion (Takakura et al.,
07; Takemoto et al., 2005).
Our previous study showed that a prime-boost adminis-
tration of 4  M2e.HSP70c (r4M2e/H70c) formulated in
F105 buffer provided full protection against lethal dose of
mouse-adapted H1N1, H3N2, or H9N2 inﬂuenza A viruses in
mice (Ebrahimi et al., 2012). In addition, Oral live attenuated
Salmonella Enteritidis vaccine vector expressing M2e protein
of inﬂuenza A virus in combination with CD154 without
adjuvant effectively induced M2e-dpeciﬁc IgG antibody
response in chicken and provided protection against direct
challenge with LPAI H7N2 (Layton et al., 2009).
In the present study, 30 mg of r4M2e/H70c without
adjuvant compared to HA-based vaccine formulated with
MF59 adjuvant enhanced humoral and cell-mediated
immune responses in chickens. In addition, increase of
HI antibody titers against H9N2 virus in all M2e- or HA-
based vaccinated birds after challenge indicated that the
challenge virus replicated in all immunized groups.
Oropharyngeal and cloacal shedding of the virus was
detected in all of the r4M2e/H70c vaccinated birds at
2 days after challenge, but the titer was low and decreased
rapidly to reach undetectable levels at 7 days after
challenge. These results agreed with the clinical signs
observed and suggest higher resistance of the birds
vaccinated with r4M2e/H70c to the challenge strain. This
result not only exactly agreed with our previous study in
mice (Ebrahimi et al., 2012), but it was generally in
accordance with the previous reports on M2e-based
vaccines in mice (Wu et al., 2007; Ernst et al., 2006; Sealy
et al., 2003; Huleatt et al., 2008).
Anti-M2e antibodies are not neutralizing antibodies;
however, they are capable of binding to the M2 proteins
that are abundantly presented on the surface of the
infected cells to eliminate inﬂuenza virus-infected cells
through antibody-dependent cell-mediated cytotoxicity
(ADCC) and/or phagocytosis (Jegerlehner et al., 2004;
Tompkins et al., 2007). Furthermore, they are predicted to
limit the severity of inﬂuenza A disease by its inhibitory
role on the uncoating of viral particles in endosomes
(Betakova, 2007). As a result, the induced anti-M2e
antibodies can delay the onset of morbidity and allow
the host immune response to develop adaptive immunity
to the dominant neutralizing inﬂuenza antigen, HA.
Therefore, humoral immune responses against HA pro-
voked by infection could help to reduce viral replication in
the respiratory system.
This explanation can be considered not only by the
results of our previous study in mice (Ebrahimi et al.,
2012), but in the present study induced HA-speciﬁc serum
antibody was detected by day 7 after challenge (Fig. 2).
Other published studies also reported the detection of HA-
speciﬁc serum antibody by day 5 to 6 after challenges with
signiﬁcant impact to restrict viral replication in the
respiratory system (Fabrice et al., 2008; Lincoln et al.,
2010; Sealy et al., 2003).
With regard to the above explanation and considering
that the replication of the challenge inﬂuenza virus can
induce a signiﬁcant increase in the HA-speciﬁc serum
antibody titers and the absence of this antibody increase
suggests that the challenge virus did not replicate to a
signiﬁcant degree. Consequently, it seems that the recovery
of r4M2e/H70c vaccinated birds with the low level of
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M. Dabaghian et al. / Veterinary Microbiology 174 (2014) 116–126 125A-speciﬁc antibody (Fig. 2) by day 5 after challenge is likely
ontributed to induced HA-subtype speciﬁc neutralizing
ntibody.
Clinical signs and shedding levels could not be used
ere as the only criteria to compare the efﬁcacy of the
ifferent vaccine schemes. Therefore, another way to
valuate indirectly the efﬁcacy of vaccines was to compare
e activation and proliferation of lymphocytes as a critical
ole in inducing both the humoral and cellular immune
esponses after immunization.
Our results showed that the T cells of chickens
munized with r4M2e/H70c or r4M2e in the absence of
ny adjuvant exhibited a proliferative response. However,
e level of M2e-speciﬁc T-cell proliferative responses in the
hickens immunized with r4M2e/H70c was signiﬁcantly
igher than that in the chickens immunized with the r4M2e
accine. These data clearly showed that mHSP70c is a strong
djuvant that modulates the immune response toward the
duction of strong cellular response with a Th-1 cytokine
roﬁle.
In this study, protection against H9N2 viral challenge
as signiﬁcantly increased in chickens by injection of
4M2e/H70c compared with injection of Con/HA or r4M2e.
his protective immunity might be attributed to enhanced
ell-mediated immunity, which is interpreted as increased
mphocytes proliferation, increased levels of Th1-type
FN-g) and Th2-type (IL-4) cytokines production and
creased CD4+ to CD8+ ratios, resulting from the injection
f r4M2e genetically fused to mHSP70c. These results are
onsistent with previous reports on antibodies and cell-
ediated cytotoxicity speciﬁc to the M2e antigen fused to
SP-1 or in combination with nucleotide based CPG-ODN
djuvant and their anti-viral activity (Wu et al., 2009; Zhao
t al., 2010).
In Conclusion, this is the ﬁrst report of a challenge study
valuating the immunogenicity and protective efﬁcacy of
n E. coli-expressed 4  M2e.HSP70c formulated in F105
uffer as a universal inﬂuenza vaccine candidate by a
rime-boost vaccination regime against inﬂuenza virus in
hickens. As, protective immune responses against inter-
al pathogens like viruses are known to require a balance
etween Th-2 and Th-1 response patterns with the
roduction of type 1 cytokines such as IFN-g and
ntibodies of the IgG2a isotype in mice (Stevens et al.,
988; Unkeless et al., 1988). Accordingly, our data reported
erein show that vaccination with r4M2e/H70c promoted
 cellular immune response characterized by increased
vels of Th1-type (IFN-g) and Th2-type (IL-4) cytokines
roduction and increased CD4+ to CD8+ ratios.
Moreover, comparison of protective efﬁcacy against
PAI H9N2 in birds intramuscularly immunized with
9N2/Iran vaccine or r4M2e/H70c fusion protein likely
epresented the ability of the M2e-based vaccine in
roviding cross-protection against heterosubtypic H9N2
hallenge and also allowed the host immune system to
duce HA-homosubtype neutralizing antibody against
9N2 challenge. Consistently, HA-speciﬁc neutralizing
ntibody was reported herein to have sub-typically
igniﬁcant impact on inﬂuenza virus replication by day
 after challenge, these result is in accordance with
the cross-protection was contributed to inﬂuenza-speciﬁc
CTL activity (cell-mediated immunity).
Taking to gather, the M2e based-vaccine could not
prevent the viral infection but rather suppresses the
symptoms of virus-infected chickens by reducing the virus
shedding in chicken. It will be worthwhile to evaluate the
immune response further in the chicken model with other
formulation of r4M2e/H70c by different routs of injection.
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